Navigation Links
Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.
Date:11/11/2013

BOSTON, Nov. 11, 2013 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of ViroPharma Inc. ("ViroPharma" or the "Company") (NASDAQ:   VPHM) concerning the proposed acquisition of the Company by U.K.-based company, Shire PLC ("Shire"), in a transaction valued at approximately $4.2 billion.  Under the terms of the transaction, Shire will acquire each ViroPharma share for $50.00, representing a paltry premium of 27% to ViroPharma's closing share price on Friday, November 8, 2013.   

The transaction was announced less than two weeks after ViroPharma announced highly positive third quarter 2013 financial results, which management described as an "extremely strong period of growth and positive momentum across our entire organization."  At that time, the Company also raised its North American net sales guidance to between $395 and $405 million. 

ViroPharma's share price has been spiking over the last year - trading between $22.12 per share on December 31, 2012 and hitting a high of $41.14 on November 7, 2013.  Indeed, in September 2013, the Company's share price rose nearly 30%.  The so-called premium appears to significantly undervalue the Company, especially considering that several companies, including Sanofi, were apparently interested in ViroPharma, which makes Cinryze for the treatment of immune disorder hereditary angioedema.  Treatments for such rare disorders can command huge prices, running into hundreds of thousands of dollars a year per patient.

Block & Leviton's investigation seeks to determine, among other things, whether ViroPharma's Directors breached their fiduciary duties by failing to maximize shareholder value in the proposed acquisition by Shire and the fairness by which the ViroPharma's Directors considered and approved the transaction.

If you are a ViroPharma shareholder and have questions about your legal rights, or if you have information relevant to this investigation, please contact attorney Steven P. Harte, at
(617) 398-5600 or email him at Steven@blockesq.com.  

Block & Leviton is a Boston-based law firm representing investors nationwide for violations of securities laws.  The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 50 years.  This notice may constitute attorney advertising.

Contact:
BLOCK & LEVITON LLP
Steven P. Harte, Esq.
steven@blockesq.com
(617) 398-5600


'/>"/>
SOURCE Block & Leviton LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Too Much Sugar on the Menu? A New Tablet Might Someday Block Those Carbs
2. ACI: Drug and Medical Device Litigation Conference - Blockbuster Faculy Announced
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
5. UK Ministers to Block Law against Headshops
6. Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia
7. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
8. Stenting blocked bowel arteries saves lives
9. Blockbuster Expectations Dont Always Translate to Market Reality
10. Block Engineering Announces Collaborative Agreement with Pfizer for Next Generation Cleaning Verification Technology
11. Missouris PSE Blocking Technology Leading To Progress In Battle Against Meth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... N.Y. (PRWEB) , ... October 11, 2019 , ... ... — the regulated cannabis industry’s national resource — held the grand opening for ... New York, STOA Wellness offers a thoughtfully curated lineup of CBD wellness products ...
(Date:10/10/2019)... ... October 10, 2019 , ... Hospice of Westchester ... September 26, at the Westchester Country Club in Rye. The event honored Grassy ... organization and its mission. , “In Celebration” featured live entertainment, culinary delights and ...
(Date:10/9/2019)... ... 09, 2019 , ... Drs. Steven White, Brad Haines and Colton Fischer of ... apnea in Davidson, NC. If left untreated, sleep apnea can cause mental health ... a skilled dentist, those who suffer from snoring at night and excessive fatigue during ...
Breaking Medicine Technology:
(Date:10/8/2019)... ... October 08, 2019 , ... What unique insights can three former Surgeons General ... wellness in the nation? That question will be answered at ICAA 2019: Shaping the ... Expo. The event will take place October 10-12, 2019, at the Gaylord Palms Resort ...
(Date:10/8/2019)... San Jose, CA (PRWEB) , ... October 08, 2019 , ... ... patients with gum disease in San Jose, CA experience relief from this common and ... as possible in order to save adults from living with uncomfortable symptoms, including tender ...
(Date:10/8/2019)... Md. (PRWEB) , ... October 08, 2019 , ... ... fungal infection progression in live samples, Meiqing Shi, associate professor with the University ... field. In his latest paper published in Nature Communications, Shi and his lab ...
(Date:10/8/2019)... ... October 08, 2019 , ... At the ... 4medica® President Gregg Church will inform conference attendees how the 4medica ... management-by starting with the right, clean patient data. The single platform interfaces to ...
(Date:10/8/2019)... ... 2019 , ... The University of California San Francisco (UCSF) ... Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic category. The ... better, more cost-effective healthcare by improving outcomes such as shorter hospital stays, reduced ...
Breaking Medicine News(10 mins):